drugset / Trial / NCT00203307

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

NCT00203307

RandomizedCrossoverDouble-blindTreatment

Summary

Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study. The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.

Timeline

Start
2004-05
Primary completion
2006-03
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule

Indications